Amgen Completes Acquisition of Alantos

07-19-2007: Amgen announced the completion of its acquisition of Alantos, a private company developing drugs for the treatment of diabetes and inflammatory diseases. The transaction provides Amgen with Alantos's DPP-IV inhibitor in clinical development (Phase 2a) for the treatment of type II diabetes as well as its matrix metalloproteinases platform for osteoarthritis. The acquisition was originally announced June 6.

Watchlist

This is where you can add this news to your personal favourites

On my watchlist

Facts, background information, dossiers

Amgen
osteoarthritis
inhibitor

inflammatory diseases
inflammation
inflammatory disease

More about Amgen

News

Amgen Completes Acquisition of Alantos

Amgen announced the completion of its acquisition of Alantos, a private company developing drugs for the treatment of diabetes and inflammatory diseases. The transaction provides Amgen with Alantos's DPP-IV inhibitor in clinical development (Phase 2a) for the treatment of type II diabetes a ... more

Amgen Dedicates Cambridge, Mass. Research Center Focusing On Small Molecule Drug Discovery

Amgen (NASDAQ:AMGN) today dedicated its 285,000 square foot research facility in the heart of the Cambridge-Boston biotechnology corridor. Amgen's work in the state-of-the-art, eight-story laboratory and research facility will focus on researching and discovering small molecule drug candi ... more

FDA Approves Amgen's Aranesp™ For Anemia

Amgen (Nasdaq:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved AranespÔ (darbepoetin alfa) for the treatment of anemia associated with chronic renal failure. Aranesp requires fewer injections than the existing treatment, Epoetin alfa, which is marketed u ... more

More news by Amgen